Posted On: 03/08/2016 8:07:03 PM
Post# of 30035
Thanks for posting when it came out today.
Not sure this was widely known. Lonza didn't pocket the $3M. Obviously a $8B company wants this to success as do many others.
Add to that the DoD is picking up most the expense of the trial.
Quote:
To acquire the rights to ESS, Amarantus paid Lonza Group a fee of $3.15 million in cash. In return, Lonza has committed to spending a good portion of the payment on preparing the initiation of the Phase II clinical study.
Not sure this was widely known. Lonza didn't pocket the $3M. Obviously a $8B company wants this to success as do many others.
Add to that the DoD is picking up most the expense of the trial.
(3)
(2)Scroll down for more posts ▼
